Patents by Inventor Annie Andrieux

Annie Andrieux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases
    Patent number: 11613753
    Abstract: Using chemical proteomics with a potent unique irreversible inhibitor, inventors found that major brain tubulin carboxypeptidase (TCP) is a complex of vasohibin-1 (VASH1) with the Small Vasohibin-Binding Protein (SVBP). VASH1 and its homologue vasohibin-2 (VASH2), when complexed with SVBP, exhibit robust and specific Tyr/Phe carboxypeptidase activity on microtubules. Accordingly inventors are the first to identify the enzymatic activity of vasohibin and vasohibin/SVBP complex. Knock down of vasohibins or SVBP in cultured neurons results in a marked reduction of tyrosinated ?-tubulin levels and onset of severe differentiation defects. Furthermore, knock down of vasohibins disrupts neuronal migration in developing mouse neocortex. These results establish vasohibin/SVBP complexes as TCP enzymes.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 28, 2023
    Assignees: LES LABORATOIRES SERVIER, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Annie Andrieux, Marie-José Moutin, Christophe Bosc, Chrystelle Aillaud, Leticia Peris, Philippe Delagrange
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING TUBULIN CARBOXYPEPTIDASES ASSOCIATED DISEASES
    Publication number: 20200407726
    Abstract: Using chemical proteomics with a potent unique irreversible inhibitor, inventors found that major brain tubulin carboxypeptidase (TCP) is a complex of vasohibin-1 (VASH1) with the Small Vasohibin-Binding Protein (SVBP). VASH1 and its homologue vasohibin-2 (VASH2), when complexed with SVBP, exhibit robust and specific Tyr/Phe carboxypeptidase activity on microtubules. Accordingly inventors are the first to identify the enzymatic activity of vasohibin and vasohibin/SVBP complex. Knock down of vasohibins or SVBP in cultured neurons results in a marked reduction of tyrosinated ?-tubulin levels and onset of severe differentiation defects. Furthermore, knock down of vasohibins disrupts neuronal migration in developing mouse neocortex. These results establish vasohibin/SVBP complexes as TCP enzymes.
    Type: Application
    Filed: October 26, 2018
    Publication date: December 31, 2020
    Inventors: Annie ANDRIEUX, Marie-José MOUTIN, Christophe BOSC, Chrystelle AILLAUD, Leticia PERIS, Philippe DELAGRANGE
  • Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
    Patent number: 8513280
    Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: August 20, 2013
    Assignees: Institut National de la Sante et de la Recherche Medicale, Commissariat a l'Energie Atomique, Gesellschaft fur Biotechnologische Forschung mbH (GBF)
    Inventors: Annie Andrieux, Didier Job, Annie Schweitzer, Gerhard Höfle
  • Transgenic or recombinant non-human mammals and their uses in screening psychoactive medicines
    Patent number: 8198507
    Abstract: The invention concerns transgenic or recombinant non-human mammals, wherein the expression of the gene coding for a microtubule associated protein (MAP) is modified (STOP gene) (inactivation or overexpression) and their uses in screening medicines useful in schizophrenia and schizo-affective disorders, with anxious, paranoiac or depressive component.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: June 12, 2012
    Assignees: Institut National de la Sante Et de la Recherche Medicale - INSERM, Commissariat a l'Energie Atomique Et Aux Energies Alternatives
    Inventors: Annie Andrieux, Didier Job, Eric Denarier, Christophe Bosc, Muriel Vernet
  • Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
    Publication number: 20110118317
    Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect.
    Type: Application
    Filed: September 9, 2010
    Publication date: May 19, 2011
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Commissariat a l'Energie Atomique (CEA), Helmholtz Zentrum Fur Infektionsforschung GMBH (HZI)
    Inventors: Annie Andrieux, Didier Job, Annie Schweitzer, Gerhard Höfle
  • Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
    Patent number: 7816370
    Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect, such as schizophrenia or autism.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: October 19, 2010
    Assignees: Institut National de la Sante et de la Recherche Medicale, Commissariat a l'Energie Atomique, Helmhaltz Zentrum Fur Infektions Forschung GmbH
    Inventors: Annie Andrieux, Didier Job, Annie Schweitzer, Gerhard Höfle
  • Transgenic or recombinant non-human mammals and their uses in screening psychoactive medicines
    Publication number: 20090064353
    Abstract: The invention concerns transgenic or recombinant non-human mammals, wherein the expression of the gene coding for a microtubule associated protein (MAP) is modified (STOP gene) (inactivation or overexpression) and their uses in screening medicines useful in schizophrenia and schizo-affective disorders, with anxious, paranoiac or depressive component.
    Type: Application
    Filed: May 14, 2007
    Publication date: March 5, 2009
    Inventors: Annie Andrieux, Didier Job, Eric Denarier, Christophe Bosc, Muriel Vernet
  • Use of Epothilones in the Treatment of Neuronal Connectivity Defects Such as Schizophrenia and Autism
    Publication number: 20080207697
    Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect, such as schizophrenia or autism.
    Type: Application
    Filed: January 28, 2005
    Publication date: August 28, 2008
    Inventors: Annie Andrieux, Didier Job, Annie Schweitzer, Gerhard Hofle
  • Transgenic or recombinant non-human mammals and their uses in screening psychoactive medicines
    Publication number: 20040093625
    Abstract: The invention concerns transgenic or recombinant non-human mammals, wherein the expression of the gene coding for a microtubule associated protein (MAP) is modified (STOP gene) (inactivation or overexpression) and their uses in screening medicines useful in schizophrenia and schizo-affective disorders, with anxious, paranoiac or depressive component.
    Type: Application
    Filed: November 17, 2003
    Publication date: May 13, 2004
    Inventors: Annie Andrieux, Didier Job, Eric Denarier, Christophe Bosc, Muriel Vernet